



## Index

*Note:* Page numbers of article titles are in **bold face** type.

### A

- Abdominal pain, in eating disorders, 1164
- Acute stress disorder, 1113–1114, 1128
- Adaptation, disordered, of ADHD, 1023
- ADHD. *See* Attention-deficit/hyperactivity disorder.
- Adjustment disorder, anxiety with, 1114, 1129
- Aerosol spray inhalation, 1186–1190
- Aggressive behavior, 964–965, 970–971, 984
- Agoraphobia, 1111–1112, 1128
- Alcohol abuse, 1195–1198
- Alkalosis, metabolic, in eating disorders, 1164–1165
- Alpha<sub>2</sub>-agonists  
for ADHD, 1060, 1076–1077  
for anxiety disorders, 1122
- Alprazolam, for anxiety disorders, 1121–1122, 1125–1126, 1129, 1132
- Amenorrhea, in eating disorders, 1165–1166
- Amitriptyline, for anxiety disorders, 1122–1123
- Amphetamines  
abuse of, 1199–1200, 1210  
for ADHD, 1060, 1073–1075
- Anabolic steroids, misuse of, 1211–1214
- Angel dust (phencyclidine), 1206
- Anorexia, methylphenidate-induced, 1069–1070
- Anorexia nervosa. *See* Eating disorders.
- Antidepressants  
for ADHD, 1060, 1077–1082  
for anxiety disorders, 1122–1123, 1130–1131  
for depression, 1100–1112
- Anxiety and anxiety disorders, **1107–1138**  
adjustment disorder with, 1114, 1129  
assessment of, 1114–1117  
attention-deficit/hyperactivity disorder with, 1123–1124  
clinical presentation of, 1109–1110  
comorbidity with, 1108  
course of, 1109–1110  
epidemiology of, 1107  
generalized, 1114, 1129  
genetic factors in, 1108  
rating scales for, 1116  
stimulant-induced, 1073  
substance-induced, 1114  
treatment of, 1117–1132  
types of, 1110–1114  
versus attention-deficit/hyperactivity disorder, 1040
- Appetite suppression  
in psychiatric disorders, 1142  
methylphenidate-induced, 1069–1070
- Athletes  
drug misuse by, 1211–1214  
eating disorders in, 1171–1172
- Atomoxetine, for ADHD, 1060, 1080–1081
- Attention-deficit/hyperactivity disorder, **1019–1048**  
anatomic lesions in, 1021–1022  
anxiety disorder with, 1123–1124  
assessment of, 1032–1043  
behavior documentation in, 1033–1034  
behavioral inhibition theory of, 1023–1024  
biochemical alterations in, 1022  
brain dysfunction in, 1021  
coexisting conditions with, 1036–1041  
combined type, 1025  
core symptoms of, 1034–1036  
definition of, 1020  
developmental variations in, 1027–1030  
diagnosis of, 1024–1032, 1043–1044  
differential diagnosis of, 1037–1038

- disordered adaptation theory of, 1023  
 epidemiology of, 1019, 1032  
 etiology of, 1021–1024  
 functional impairment in, 1031–1032  
 genetic factors in, 1022  
 history of, 1006, 1019–1020  
 hyperactivity in, 1026–1028  
 impulsivity in, 1026–1028  
 inattention in, 1025–1026, 1029–1030  
 interventions for, **1049–1092**  
   pharmacologic, 1058–1082  
     alpha<sub>2</sub>-agonists, 1060,  
       1076–1077  
     antidepressants, 1060,  
       1077–1082  
     efficacy of, 1067–1068  
     medications for, 1060, 1062  
     principles of, 1061–1062  
     stimulants, 1060, 1062–1076  
     versus psychological,  
       1058–1060  
   psychologic, 1049–1060  
     behavior therapy, 1050–1051  
     biofeedback, 1052  
     cognitive-behavior therapy,  
       1051–1052  
     psychosocial treatments,  
       1052–1068  
     psychotherapy, 1050  
     versus pharmacologic,  
       1058–1060  
 neuropsychological deficits in, 1023  
 predominantly hyperactive-impulsive  
   type, 1025  
 predominantly inattentive type, 1025  
 school professional observations in,  
   1035–1036  
 screening for, 1033  
 Tourette's syndrome with, 1071–1072  
 types of, 1025–1026
- B**
- 
- Barbiturates, abuse of, 1211, 1214  
 Behavior therapy, for ADHD, 1050–1051  
 Behavioral inhibition theory, of ADHD,  
   1023–1024  
 Behavioral problems  
   anxiety. *See* Anxiety and  
     anxiety disorders.  
   attention-deficit/hyperactivity disorder.  
     *See* Attention-deficit/  
       hyperactivity disorder.  
   bullying, 964–965, 970–971, 984  
   depression. *See* Depression.  
   disruptive, **1005–1017**  
   eating disorders. *See* Eating disorders.  
   substance abuse. *See* Substance abuse.  
   violence. *See* Violence.  
 Benzodiazepines, for anxiety disorders,  
   1121–1122, 1125–1126, 1129, 1132  
 Biofeedback, for ADHD, 1052  
 Bipolar disorder  
   ADHD with, 1073  
   presentation of, with major depression,  
     1095–1096  
 Body dissatisfaction, eating disorders  
   in, 1145  
 Bone density, low, in eating disorders, 1166  
 Bradycardia, in eating disorders, 1165  
 Bulimia nervosa. *See* Eating disorders.  
 Bullying behavior, impact of, 964–965,  
   970–971, 984  
 Buprenorphine, for opiate addiction, 1205  
 Bupropion  
   for ADHD, 1060, 1080  
   for cocaine addiction, 1202  
   for nicotine addiction, 1194–1195  
 Buspirone, for anxiety disorders, 1122
- C**
- 
- Cardiac arrhythmias, in eating disorders, 1165  
 Child abuse, violence in, 984–985  
 Chloral hydrate, for anxiety disorders, 1132  
 Cigarette smoking, 1188, 1190–1195  
 Citalopram  
   for anxiety disorders, 1120  
   for obsessive-compulsive disorder, 1126  
 Clomipramine  
   for anxiety disorders, 1122–1123, 1125,  
     1131  
   for obsessive-compulsive disorder, 1126  
 Clonazepam, for anxiety disorders,  
   1121–1122, 1125–1126, 1129  
 Clonidine  
   for ADHD, 1060, 1076–1077  
   for anxiety disorders, 1122  
 Cocaine abuse, 1201–1203  
 Cognitive-behavioral therapy  
   for ADHD, 1051–1052  
   for anxiety disorders, 1125  
   for school phobia, 1127  
 Collective violence, 980–981

- Conduct disorders, 1007–1010
  - adult onset type, 1008–1009
  - course of, 1008–1009
  - definition of, 1005
  - diagnosis of, 1009–1010
  - differential diagnosis of, 1013–1014
  - epidemiology of, 1007
  - etiology of, 1007–1008
  - history of, 1006–1007
  - types of, 1006
- Constipation, in eating disorders, 1164
- Contingency management, for ADHD, 1050–1051
- Coping, with eating disorders, 1163
- Crack cocaine, 1201–1203
- Crimes, violence in, 973, 988–989

## D

---

- Date rape drugs, 1207–1210
- Dating violence, 964–965, 978, 986–987
- Denial, in eating disorders, 1140, 1169
- Depression, **1093–1106**
  - anxiety disorders with, 1108
  - bipolar disorder development from, 1095–1096
  - clinical description of, 1094–1096
  - comorbid conditions with, 1097
  - differential diagnosis of, 1098
  - epidemiology of, 1093–1094
  - etiology of, 1096–1097
  - legal issues in, 1103–1104
  - prognosis for, 1103
  - stimulant-induced, 1073
  - treatment of, 1098–1103
  - versus ADHD, 1039–1040

- Desipramine
  - for ADHD, 1060, 1078–1080
  - for anxiety disorders, 1122–1123
  - for depression, 1110

- Dexamethasone suppression test, in depression, 1097
- Dexamethylphenidate, for ADHD, 1066
- Dextroamphetamine, for ADHD, 1060, 1073–1074
- Diabetes mellitus, eating disorders in, 1172–1173
- Diazepam, for anxiety disorders, 1126
- Dieting, 1141
- Diphenhydramine, for anxiety disorders, 1122

- Discipline, violence in, 964–965, 975–978, 984, 992–994
- Disordered adaptation theory, of ADHD, 1023
- Disruptive behavioral disorders, **1005–1017**
  - conduct disorders, 1005–1010, 1012–1015
  - differential diagnosis of, 1013–1014
  - evaluation of, 1012–1013
  - history of, 1006–1007
  - not otherwise specified, 1005–1006, 1012
  - oppositional defiant disorder, 1005–1006, 1010–1015
  - treatment of, 1014–1015
  - types of, 1005
- Domestic violence, 964–965, 974–975
- Dopamine, in ADHD, 1022
- Doxepin, for anxiety disorders, 1122–1123
- Drug abuse. *See* Substance abuse.

## E

---

- Eating disorders, **1139–1177**
  - assessment of, 1151–1159
  - background factors in, 1144–1147
  - causes of, 1143–1151
  - complications of, 1157–1159
  - definitions of, 1140–1143
  - epidemiology of, 1139
  - in athletes, 1171–1172
  - in diabetes mellitus, 1172–1173
  - in prepubertal children, 1169–1170
  - in psychiatric disorders, 1142
  - laboratory testing in, 1153–1155
  - obesity and, 1141–1142, 1145, 1170–1171
  - parents facilitation of, 1149
  - perpetuating factors in, 1148–1151, 1163–1164
  - persistent, 1168
  - personality tendencies in, 1146
  - physiologic changes in, 1148–1149
  - precipitating factors in, 1147–1148
  - recovery from, 1167–1169
  - relapse in, 1168
  - screening for, 1151
  - short-term, 1142
  - treatment of, 1159–1169
  - versus feeding disorders, 1141
  - versus normal eating, 1143–1144
- Ecstasy, 1206–1207
- Environmental factors, in conduct disorders, 1008

Executive functioning, deficits in, in  
ADHD, 1023

Exercise, excessive, in eating disorders, 1158

**F**


---

Family, eating disorders and, 1146, 1162–1163

Feeding disorders, versus eating disorders, 1141

Fighting, violence in, 985

Films, violence in, impact of, 970

Firearms, violence related to, 972, 991–992

Fluid and electrolyte imbalance, in eating disorders, 1164–1165

Flunitrazepam, abuse of, 1208–1209

Fluoxetine  
for anxiety disorders, 1120, 1130  
for obsessive-compulsive disorder, 1126

Fluvoxamine  
for anxiety disorders, 1120, 1131  
for generalized anxiety disorder, 1129  
for obsessive-compulsive disorder, 1126  
for separation anxiety disorder, 1128  
for social phobia, 1127–1128

Food, refusal of, 1141

Food avoidance emotional disorder, 1140

Functional analysis, for ADHD, 1050

Functional impairment, in ADHD, 1031–1032

**G**


---

Gamma-hydroxybutyrate, abuse of, 1209–1210

Gang violence, 973, 989

Gasoline, inhalation of, 1187

Gastrointestinal symptoms, in eating disorders, 1164

Gender differences, in eating disorders, 1144–1145

Generalized anxiety disorder, 1114, 1129

Genetic factors  
in ADHD, 1022  
in conduct disorders, 1008  
in depression, 1097  
in eating disorders, 1145  
in panic disorder, 1112

Group therapy, for eating disorders, 1161

Growth retardation, methylphenidate-induced, 1069–1070

Guanfacine, for ADHD, 1060, 1077

Guns, violence related to, 972, 991–992

**H**


---

Hallucinogenic drugs, abuse of, 1205–1207

Hate groups and crimes, violence in, 973, 989

Headache, methylphenidate-induced, 1069

Hepatitis, pemoline-induced, 1075–1076

Herbal medicine, for ADHD, 1082

Heroin abuse, 1203–1205

Homicides, 979–980

Hydroxyzine, for anxiety disorders, 1122

Hyperactivity, in ADHD, 1026–1028

Hypochloremia, in eating disorders, 1164–1165

Hypophosphatemia, in eating disorders, 1165

**I**


---

Ibogaine, for cocaine addiction, 1203

Imipramine  
for ADHD, 1060, 1078–1080  
for anxiety disorders, 1125, 1131–1132  
for depression, 1110  
for school phobia, 1127  
for separation anxiety disorder, 1128

Impulsivity, in ADHD, 1026–1028

Inattention, in ADHD, 1025–1026, 1029–1030

Infant(s), ADHD in, 1027–1029

Inhalant drugs, abuse of, 1186–1190

**K**


---

Ketamine, abuse of, 1210

**L**


---

Laxatives, abuse of, in eating disorders, 1158, 1164

Legal issues, in depression, 1103–1104

Levomethyl acetate, for opiate addiction, 1205

Lorazepam, for anxiety disorders,  
1121–1122, 1126

Lysergic acid diethylamide (LSD), 1205

## M

---

Magnetic resonance imaging, in ADHD,  
1021–1022

Marijuana use, 1198–1199

Media violence, impact of, 970

Menstrual disorders, in eating disorders,  
1165–1166

Metabolic alkalosis, in eating disorders,  
1164–1165

Methadone, for opiate addiction, 1204–1205

Methamphetamine  
abuse of, 1200  
for ADHD, 1074

3,4-Methylenedioxymethamphetamine  
(ecstasy), 1206–1207

Methylphenidate, for ADHD  
abuse of, 1072, 1210  
adverse effects of, 1060, 1068–1073  
dose for, 1060, 1064, 1066–1067  
drug interactions with, 1069  
duration of action of, 1064–1066  
efficacy of, 1067–1068  
failure of, 1064  
long-acting, 1064–1067  
mechanism of action of, 1063–1064  
pharmacokinetics of, 1064  
preparations for, 1063, 1066–1067  
rebound with, 1071  
tolerance of, 1070–1071

Metoclopramide, for eating disorders, 1164

Modafinil, for ADHD, 1081

Mutilation, self-, 978–979, 987

Mutism, selective, 1111, 1127–1128

## N

---

Naloxone, for opiate addiction, 1204

Nicotine addiction, 1188, 1190–1195

Norepinephrine, in ADHD, 1022

Norepinephrine reuptake inhibitors, for  
ADHD, 1060

Nortriptyline  
for ADHD, 1060, 1078–1080  
for anxiety disorders, 1122–1123

## O

---

Obesity

causes of, 1141–1142  
eating disorders in, 1145, 1170–1171

Obsessive-compulsive disorder,  
1112–1113, 1128  
diagnosis of, 1116–1117  
treatment of, 1119, 1126–1127  
versus ADHD, 1041

Oligomenorrhea, in eating disorders,  
1165–1166

Opiates, abuse of, 1203–1205

Oppositional defiant disorder, 1010–1012  
course of, 1011  
definition of, 1005  
diagnosis of, 1011–1012  
differential diagnosis of, 1013–1014  
epidemiology of, 1010  
etiology of, 1010–1011  
history of, 1006–1007  
pervasive, 1011  
situational, 1011  
versus ADHD, 1039

Osteoporosis, in eating disorders, 1166

## P

---

Panic disorder, 1111–1112, 1128

Parents, training for, for ADHD management,  
1053–1055

Paroxetine  
for anxiety disorders, 1120, 1130  
for obsessive-compulsive disorder,  
1126–1127  
for social phobia, 1127–1129

Pediatric autoimmune neuropsychiatric  
disorders associated with streptococcal  
infection (PANDAS), 1113, 1119

Peer mediation programs, for ADHD,  
1057–1058

Pemoline, for ADHD, 1060, 1075–1076

Pentobarbital, abuse of, 1211

Phencyclidine, 1206

Phobias, 1112, 1126, 1128

Physical fighting, 985

Posttraumatic stress disorder, 1108,  
1113–1114, 1129

Psychosocial treatments, for ADHD,  
1052–1058

- Psychotherapy  
 for ADHD, 1050  
 for anxiety disorders, 1118–1119,  
 1124–1125
- Punishment, corporal, violence in, 964–965,  
 975–978, 984, 992–994

## R

---

- Rape  
 date rape drugs and, 1207–1210  
 violence in, 964–965, 978, 990–991
- Rebelliousness, in eating disorders, 1149
- Restrained eating, 1141
- Restrictive eating, 1141
- Rumination syndrome, 1142

## S

---

- School  
 ADHD intervention training in,  
 1055–1058  
 violence in, 980, 982–983, 985–986
- School-aged children  
 ADHD in, 1027–1029  
 eating disorders in, 1169–1170
- Secobarbital, abuse of, 1211
- Selective eating, 1141
- Selective mutism, 1111, 1127–1128
- Selective serotonin reuptake inhibitors  
 for ADHD, 1078–1080  
 for anxiety disorders, 1120, 1130–1131  
 for depression, 1110–1111  
 for eating disorders, 1166–1167  
 for obsessive-compulsive disorder, 1126
- Self-management, of ADHD, 1050–1051
- Self-mutilation, 978–979, 987
- Separation anxiety disorder, 1111, 1128
- Sertraline  
 for ADHD, 1073  
 for anxiety disorders, 1120, 1130  
 for obsessive-compulsive disorder,  
 1126–1127  
 for selective mutism, 1127
- Sexual assault, violence in, 964–965, 978,  
 990–991
- Sinus bradycardia, in eating disorders, 1165
- Sleep disorders, from stimulants, for  
 ADHD, 1071

- Sleep electroencephalography, in  
 depression, 1097
- Smoking, 1188, 1190–1195
- Social phobia, 1112, 1126–1129
- Social skills training, for ADHD, 1052–1053
- Solvent inhalation, 1186–1190
- Spanking, impact of, 964–965, 975–978, 984,  
 992–994
- Sports  
 drug misuse in, 1211–1214  
 eating disorders in, 1171–1172
- Stimulants  
 abuse of, 1210  
 for ADHD, 1060, 1062–1076  
 amphetamines, 1060, 1073–1075  
 benefits of, 1062  
 history of, 1062  
 methylphenidate.  
   *See* Methylphenidate.  
 pemoline, 1060, 1075–1076
- Streptococcal infections, pediatric autoimmune  
 neuropsychiatric disorders associated  
 with streptococcal infection (PANDAS)  
 after, 1113, 1119
- Stress, reactions to, 1108, 1113–1114,  
 1128–1129
- Substance abuse, **1179–1224**  
 alcohol, 1195–1198  
 amphetamines, 1199–1200  
 barbiturates, 1211  
 cocaine, 1201–1203  
 date rape drugs, 1207–1210  
 epidemiology of, 1179–1181  
 etiology of, 1181–1185  
 evaluation for, 1183, 1186  
 factors protective of, 1185  
 hallucinogenic drugs, 1205–1207  
 inhalant drugs, 1186–1190  
 list of, 1179–1180  
 marijuana, 1198–1199  
 opiates, 1203–1205  
 sport doping agents, 1211–1214  
 stimulants, 1210  
 tobacco, 1188, 1190–1195  
 violence related to, 974
- Suicide, 979, 987–988  
 in depression, 1094–1096, 1098–1099
- Support groups, for ADHD, 1053

## T

---

- Tantrums, in anxiety, 1110
- Television, violence in, impact of, 970

- Terrorism, violence in, 980–981
- Thinness, desire for, eating disorders in, 1144–1145
- Tics, ADHD with, 1071–1072
- Tobacco use, 1188, 1190–1195
- Toluene, inhalation of, 1187
- Tourette's syndrome, ADHD with, 1071–1072
- Traumatic events, reactions to, 1108, 1113–1114
- Tricyclic antidepressants  
 for ADHD, 1060, 1077–1080  
 for anxiety disorders, 1122–1123  
 for depression, 1110–1111

---

**V**

- Venlafaxine  
 for ADHD, 1081  
 for anxiety disorders, 1121, 1131  
 for generalized anxiety disorder, 1129

- Violence, **963–1003**  
 collective, 980–981  
 domestic, 964–965, 974–975  
 epidemiology of, 966, 983–992  
 etiology of, 966–968  
 firearm-related, 972, 991–992  
 gang, 973, 989  
 hate crimes, 973, 989  
 impact of, 963–965

- in bullying, 964–965, 970–971, 984  
 in child abuse, 984–985  
 in crime, 988–989  
 in dating, 964–965, 978, 986–987  
 in fighting, 985  
 in physical discipline, 964–965, 975–978, 984, 992–994  
 in school, 980, 982–983, 985–986  
 in sexual assault, 964–965, 978, 990–991  
 in substance abuse, 974  
 in terrorism, 980–981  
 in war, 980–981  
 media violence, 970  
 prevention of, 981–983  
 risk factors for, 966, 968–974  
 self-inflicted, 978–980, 987–988  
 types of, 974–981

- Vomiting, in eating disorders, 1158, 1164–1165

---

**W**

- War, violence in, 980–981
- Weapons, violence related to, 972, 991–992
- Weight loss, in eating disorders, 1152–1153

---

**Z**

- Zolpidem, for anxiety disorders, 1122